The Absence of Obstructive Sleep Apnea May Protect against Non-Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery by Corey, Kathleen Elizabeth et al.
 
The Absence of Obstructive Sleep Apnea May Protect against Non-
Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Corey, Kathleen E., Joseph Misdraji, Hui Zheng, Kyle M.
Malecki, Jacob Kneeman, Louis Gelrud, and Raymond T. Chung.
2013. The absence of obstructive sleep apnea may protect against
non-alcoholic fatty liver in patients undergoing bariatric surgery.
PLoS ONE 8(5): e62504.
Published Version doi:10.1371/journal.pone.0062504
Accessed February 19, 2015 12:08:23 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11357485
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe Absence of Obstructive Sleep Apnea May Protect
against Non-Alcoholic Fatty Liver in Patients Undergoing
Bariatric Surgery
Kathleen E. Corey
1,4*, Joseph Misdraji
2, Hui Zheng
3,4, Kyle M. Malecki
1, Jacob Kneeman
1, Louis Gelrud
5,
Raymond T. Chung
1,4*
1Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2Department of Pathology, Massachusetts General Hospital,
Boston, Massachusetts, United States of America, 3MGH Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 4Harvard
Medical School, Boston, Massachusetts, United States of America, 5Department of Internal Medicine, Bon Secours Richmond Health System, Richmond, Virginia, United
States of America
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide and its
progressive form, steatohepatitis, will be the leading indication for liver transplant by 2020. While risk factors for
steatohepatitis have been identified, little work has been performed to identify factors protective against NAFLD
development.
Aim: This study sought to identify factors predictive of normal liver histology in a bariatric cohort.
Methods: Patients undergoing weight loss surgery with liver biopsies at the time of surgery were included. Patients with
other causes of chronic liver disease were excluded.
Results: One hundred fifty-nine patients were included. Forty-nine patients had normal liver histology and 110 patients had
NAFLD. Several previously identified factors associated with normal liver histology were found. Black race was the strongest
predictor of the absence of NAFLD with an odds ratio (OR) of 6.8, 95% confidence interval (CI) 2.4–18.9. Low HOMA-IR was
also associated with normal histology (OR 1.4, 95% CI 1.03–1.9). In contrast, low HDL was associated with a decreased chance
of normal histology (OR 0.38, 95% CI 0.05–0.83). Interestingly, a novel protective factor, the absence of obstructive sleep
apnea (OSA) was strongly associated with normal histology (OR 5.6, 95% CI 2.0–16.1). In multivariate regression controlling
for BMI, black race, absence of OSA, low HOMA-IR and low ALT independently predicted normal liver histology with an area
under the ROC curve of 0.85.
Conclusions: Our study confirmed several factors associated with normal liver histology, including black race and identified
a novel factor, absence of OSA. Further evaluation of these factors will allow for improved understanding of the
pathogenesis of NAFLD.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
cause of liver disease in the United States with a growing
prevalence worldwide.[1] NAFLD is associated with an increased
risk of mortality from both liver disease and cardiovascular
disease.[2,3] Further, non-alcoholic steatohepatitis (NASH), the
progressive form of NAFLD, can lead to the development of
cirrhosis and hepatocellular carcinoma and is predicted to be the
leading indication for liver transplantation by the year 2020.[4]
With the rising prevalence of NAFLD and an increased
appreciation of its health consequences, the merit of NAFLD
screening in high risk populations has been raised. Currently, no
guidelines for NAFLD screening exist, even among high risk
patients with diabetes and obesity.[5] Screening for NAFLD
would allow for the early identification of patients with NAFLD
but would likely be prohibitive in scope and expense. Extensive
research is ongoing to identify patients at highest risk for NASH
and advanced fibrosis. In addition to the identification of risk
factors for NASH, the identification of factors that predict the
absence of NAFLD should also aid in restricting screening to highest
risk patients. The identification of protective factors against
NAFLD will contribute to an understanding of NAFLD patho-
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e62504genesis. To date, no protective factors against NAFLD have been
elucidated.
NAFLD is associated with obesity, and up to 91% of obese
adults have some form of fatty liver disease.[6,7] Importantly,
while NAFLD is common in patients with obesity, it is not
universal. This has been demonstrated in several studies of patients
undergoing weight loss surgery. At many centers, a standard of
care liver biopsy is performed at the time of weight loss surgery
because of the high prevalence of NAFLD. These biopsies have
informed many studies evaluating the prevalence of NAFLD and
paired biopsy studies have shown that NASH regresses after
bariatric surgery in up to 69.5% of patients.[7] Further, these
studies have made note of up to a 22% prevalence of normal liver
histology. However, the factors associated with normal liver
histology in patients at high risk for NAFLD are unknown.
Patients with NASH have been noted to have high rates of
atherogenic dyslipidemia, characterized by low high density
lipoprotein (HDL), high triglycerides and an increase in small
dense low density lipoproteins (LDL). Recent work from our group
has found a high prevalence of elevated non-HDL cholesterol
(non-HDL-C) in patients with NASH compared to those with
NAFLD.[8] We hypothesized that high levels of HDL and low
levels of triglyceride and non-HDL-C levels will be predictive of
the absence of NAFLD. We also hypothesized that race is
predictive of the likelihood of having NAFLD. Radiographic
NAFLD has been shown to have the highest prevalence in
Hispanic patients and lowest prevalence in African Americans.
Thus, we predict that African American race can be used along
with other factors to predict absence of histologic NAFLD. This
study sought to evaluate these and other factors to determine their
combined ability to predict normal liver histology in patients with
obesity undergoing weight loss surgery.
Materials and Methods
Ethics Statement
This study was approved by the Partners Human Research
Committee. Written informed consent was obtained from all
subjects.
Study design and population
Patients were selected from a cohort undergoing weight loss
surgery at Bon Secours Healthcare in Richmond, Virginia, from
August 2009 to July 2011. Patients age 18 or older were eligible for
participation in this study. Patients selected for weight loss surgery
did not undergo adjuvant dietary or medication treatment prior to
surgery. Patients with chronic liver disease other than non-
alcoholic fatty liver disease, as assessed by viral serologies,
autoimmune markers, iron studies and liver biopsy, were excluded
from analysis. Patients with excess alcohol use, defined as .2
drinks per day for men and .1 drink per day for women were also
excluded from the study.
Data collection
At their final pre-operative visit, patient demographic and
metabolic data were collected including age, gender, race, weight,
height, and waist and hip circumference.
Subjects were assessed by their treating physician for the
presence of co-morbid diseases including diabetes mellitus,
hypertension, obstructive sleep apnea, and dyslipidemia. Diabetes
mellitus and OSA was defined by a known prior diagnosis of
diabetes or OSA in the medical record. Hypertension was defined
by a blood pressure .=135/85 or undergoing treatment for
hypertension. Hyperlipidemia was defined as use of hyperlipid-
emic medications or a previous diagnosis of hyperlipidemia in the
medical record.
Subjects underwent fasting blood samples within 2 weeks of
their liver biopsy. Samples were analyzed for liver function tests,
insulin level, C-reactive protein, glucose level, lipid panel including
total cholesterol, LDL, HDL, and triglycerides. Non-HDL-C was
calculated by subtracting HDL cholesterol from total cholesterol
levels.
All patients had a needle liver biopsy at the time of surgery. All
liver biopsies were read by a single blinded hepatopathologist (JM).
Grade of steatosis and degree of lobular inflammation and
ballooning were assessed to calculate the NAFLD activity score
(NAS), and the NASH CRN histologic scoring system was used to
stage fibrosis.[9] NAFLD was characterized by the presence of
steatosis score of 1 or greater. Normal histology was characterized
by score of 0 for steatosis, lobular inflammation, hepatocyte
ballooning and fibrosis as well as the absence of other histologic
abnormalities.
Statistical Analysis
Statistical analysis was performed using SAS software, version
V.9.2 (SAS Institute, Cary, NC). Continuous variables were
analyzed using a Student’s t-Test while categorical variables were
analyzed using a Chi square test or Fisher’s exact test as
appropriate. Univariate analysis was used to identify factors that
significantly predicted the absence of NAFLD. Factors found to be
significant were then assessed using a multivariate linear regression
model. A multivariate logistic regression model was performed to
identify significant clinical and metabolic factors that predicted the
absence of NAFLD after adjusting for other factors including BMI.
A final logistic model was selected and the weighting for the
predictive scores were derived from the coefficients from the final
logistic model. From this fixed model a receiver operating curve
was determined and candidate thresholds for the included
variables were compared based on sensitivity and specificity. A
score was constructed based on a multivariate logistic regression
model predicting the probability for NAFLD. The model includes
race, obstructive sleep apnea, HOMA-IR and ALT as predictors
of NAFLD.
This study was approved by the Partners Human Research
Committee.
Results
Study Population Clinical Characteristics
A total of 159 patients were included in the study. Character-
istics of the patients are described in Table 1. Forty-nine patients
(30.8%) had normal liver histology, while 110 patients met criteria
for NAFLD. The mean age of patients with normal liver histology
was 40.3 years, whereas that of patients with NAFLD was
significantly higher at 47.8 years (p=0.0007). Gender and body
mass index were not significantly different between the two groups.
Black patients accounted for 57.5% of the normal group but only
19.3% of the NAFLD group (p,0.0001). Among the NAFLD
patients, 31.0% (n=34) had a NAS score of 3–4 and 25.5%
(n=28) had a NAS score .=5. The majority of NAFLD patients
had stage 0 or stage 1 fibrosis (n=97, 88%) and grade 1 steatosis
(n=61. 55.5%). (Table 2) No difference was seen in the proportion
of patients with coronary artery disease or tobacco use between the
two groups. Patients with normal histology were less likely to have
obstructive sleep apnea, diabetes mellitus or hyperlipidemia and
less likely to be on lipid lowering medications.
Sleep Apnea Absence Protects against Fatty Liver
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Patients in the normal group had lower mean ALT, glucose,
insulin, and homeostatic model assessment for insulin resistance
(HOMA-IR) than those in the NAFLD group. In addition,
patients in the normal histology group had higher mean HDL
than the NAFLD group (49.5 vs 42.3, p=0.009) and a higher
proportion of patients in the normal group had HDL.50 mg/dL
than in the NAFLD group (p=0.0098). No difference in total
cholesterol, LDL, triglycerides, or non-HDL-C was seen between
the groups.
Factors that Predicted Absence of NAFLD
Several previously identified important factors that predicted
the absence of NAFLD in obese patients were confirmed. Black
race was the strongest predictor of the absence of NAFLD and was
associated with an odds ratio (OR) of 6.8 (95% confidence interval
[CI] 2.4–18.9) for normal histology. Insulin resistance as measured
by fasting insulin, fasting glucose, diagnosis of diabetes mellitus
Table 1. Clinical Characteristics of Patients with Normal Histology and NAFLD.
Normal (n=49) N NAFLD (n=110) P Value
n( % ) n( % )
Age (years) 40.3 (10.4) 47.8 (13.6) 0.0007
Women 45 (91.8) 87 (79.1) 0.06
BMI, kg/m
2 mean(SD) 45.7 (5.4) 47.5 (8.6) 0.19
Ethnicity
White 22 (44.9) 85 (77.3)
Black 27(55.1) 25 (22.7) ,0.0001
Obstructive Sleep Apnea 9 (18.0) 65 (59.1) ,0.0001
Coronary Artery Disease 9 (18.8) 13 (9.8) 0.10
Type 2 Diabetes Mellitus 4 (8.2) 49 (36.3) 0.002
Lipid Lowering Medication Use 7 (14.3) 53 (48.2) ,0.0001
Hypertension 22 (51.2) 71 (56.4) 0.55
Hyperlipidemia 7 (14.3) 56 (44.4) 0.0003
Tobacco use 2 (4.1) 7 (6.4) 0.67
doi:10.1371/journal.pone.0062504.t001
Table 2. Liver Histology Characteristics of NAFLD Group.
NAFLD (n=110)
n( % )
Steatosis Grade
0 12 (10.9)
1 61 (55.5)
2 25 (22.7)
3 12 (10.9)
Fibrosis Stage
0 52 (47.3)
1 46 (41.8)
2 8 (7.3)
3 1 (0.9)
4 3 (2.7)
Lobular Inflammation
0 34 (30.9)
1 58 (52.7)
2 18 (16.4)
3 0( 0 )
Hepatocyte Ballooning
0 32 (29.1)
1 57 (51.8)
2 21 (19.1)
NASH Activity Score
0–2 49 (44.5)
3–4 33 (30.0)
5–8 28 (25.5)
doi:10.1371/journal.pone.0062504.t002
Table 3. Metabolic Characteristics of Patients with Normal
Histology and NAFLD.
Normal NAFLD P Value
Mean ALT, U/L (SD) 16.9 (7.9) 28.3 (27.1) 0.0042
Mean glucose, mg/dL (SD) 105.8 (35.3) 126.1 (41.1) 0.004
Mean Insulin, mU/mL (SD) 20.8 (15.1) 32.4 (29.0) 0.01
HOMA-IR (SD) 2.5 (1.6) 3.5 (1.7) 0.001
C Reactive Protein (SD) 1.1 (0.96) 1.0 (0.75) 0.64
Mean Total Cholesterol,
mg/dL
170.6 (32.7) 161.3 (40.2) 0.16
Mean HDL, mg/dL 49.5 (14.5) 42.3 (11.1) 0.009
Mean LDL, mg/dL 98.2 (24.3) 94.2 (32.7) 0.45
Mean Triglycerides, mg/dL 114.6 (64.8) 133.4 (90.2) 0.19
Mean Non-HDL
Cholesterol, mg/dl
121.1 (30.4) 119.0 (36.5) 0.73
doi:10.1371/journal.pone.0062504.t003
Sleep Apnea Absence Protects against Fatty Liver
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e62504and HOMA-IR were also predictive of normal histology. A low
HOMA-IR had the strongest association with the presence of
normal histology (OR 1.4, 95% CI 1.03–1.9). This indicates that
for each unit decrease in HOMA-IR, the risk of having normal
liver histology increases 1.4 fold. In addition, a low HDL was
associated with a decreased likelihood of normal liver histology (OR
0.38, 95% CI 0.05–0.83). No other lipid values were predictive of
normal histology, including non-HDL cholesterol. Finally, a low
ALT was associated with an increased prevalence of normal liver
histology with an OR of 1.06 (95% CI1.01–1.1).
While black race and a favorable metabolic profile have
previously been associated with normal liver histology, we
identified the absence of obstructive sleep apnea, as a novel factor
associated with normal liver histology. OSA was present in only 9
subjects (18%) with normal liver histology compared to 65 subjects
(59.1%) with NAFLD (p=,0.001). The absence of obstructive
sleep apnea was also strongly associated with the presence of
normal histology, with an OR of 5.6, (95% CI 2.0–16.1). Self-
reported use of continuous positive airway pressure (CPAP) for
OSA was not significantly different between groups but formal
compliance was not assessed.
Score to Predict Normal Histology
Multivariate regression controlling for BMI found that race,
absence of obstructive sleep apnea, HOMA-IR and ALT
predicted the presence of normal liver histology with an area
under the ROC curve of 0.85. The addition of diabetes mellitus,
glucose, insulin, age, gender, the presence of hyperlipidemia or
HDL value did not improve this model. Using the clinical and
metabolic factors that differed between the normal and NAFLD
groups, a weighted score was constructed to predict the presence
of normal liver histology.
Our predictive score is:
HealthyLiverScore~1:8 race ðÞ {1:8 sleepapnea ðÞ
{0:35 HOMAIR ðÞ {0:05 ALT ðÞ z1:5
The presence of obstructive sleep apnea is coded as 1 and the
absence as value of 0. Black race receives a value of 1 and white
patients receive a value of 0. The Healthy Liver Score values range
from 212 to 3 in our cohort. (Figure 1).
We evaluated the use of various Healthy Liver Score values to
predict normal histology (Figure 1). We found that a score of 0 or
greater maximized the combined sensitivity and specificity for
predicting normal liver histology with a sensitivity of 59.5% and
specificity of 92.7%. While this score has a relatively low
sensitivity, the high specificity minimizes the risk of falsely
predicting normal liver histology, suggesting its value as a tool to
refer patients for NAFLD screening.
We also determined the positive predictive value (PPV) and
negative predictive value (NPV) of the Healthy Liver Score. The
prevalence of normal liver histology in patients undergoing weight
loss surgery varies and can range from 1–15%.
7Using the extremes
of prevalence (1% and 15%), we predicted the relative PPV and
NPV. At the extremes of prevalence, our score had a high NPV of
99.2% at 1% prevalence and 92.8% at 15% prevalence. This
indicates that a score of ‘‘not normal’’ or less than 0 has a high
probability of correctly identifying patients with NAFLD (or those
without normal liver histology). The PPV of our score is far less:
14% at 1% prevalence and 56.2% at 15% prevalence of normal
histology. Thus, some patients without NAFLD will be placed in
the screening group but for a screening score the inclusion of
normal patients is preferable to the exclusion of abnormal (or
NAFLD) patients.
Validation Cohort
The performance of the Healthy Liver Score was evaluated in
an independent cohort of 92 subjects undergoing weight loss
surgery. Twenty-seven subjects had normal liver histology and 65
had NAFLD on liver biopsy. Using a cut-off of .=0 for normal
liver, the Healthy Liver Score had similar performance charac-
teristics with a 44.4% sensitivity and a 96.9% specificity,
replicating our findings in the initial cohort.
Discussion
This study sought to identify factors associated with normal liver
histology in patients with obesity. Identification of protective
factors can aid in guiding NAFLD screening among high risk
patients as well as further the understanding of NAFLD
pathogenesis. The inclusion of patients undergoing weight loss
surgery offers insight into a unique subset of patients: those with
normal liver biopsies that are rarely available. This cohort allows
for the identification of protective factors against the development
of histologically confirmed NAFLD in an otherwise high risk
group.
Our study confirmed several known factors associated with
normal liver histology including black race, low HOMA-IR, and
low ALT. Uniquely, we found that the absence of sleep apnea was
significantly protective against the development of NAFLD, even
when controlled for BMI. Studies suggest that obstructive sleep
apnea is associated with liver injury.[10] Chronic intermittent
hypoxia correlates with NASH activity score and fibrosis.[11] The
mechanism for this relationship remains unclear but hypoxia
induced by sleep apnea has been shown to increase expression of
lipogenic genes and decrease expression of genes regulating
mitochondrial beta oxidation in murine models leading to
increased hepatic triglyceride storage.[12] In addition, hypoxia
has been associated with increased lipid peroxidation and
increased pro-inflammatory cytokines including IL-6, chemokine
macrophage inflammatory protein-2 and IL-1b, leading to
increased hepatic inflammation in the setting of pre-existing
steatosis.[13] Our study lends further support to the notion of an
important interaction between sleep apnea and NAFLD by
demonstrating that the absence of sleep apnea may protect not only
from the development of steatohepatitis but also steatosis itself.
Further study is required to determine the impact of sleep apnea
on the development of NAFLD and the impact of effective
treatment of sleep apnea (CPAP) on NAFLD regression
Using the identified multivariate predictive factors for normal
liver histology, we constructed the Healthy Liver Score. This score
Figure 1. This figure graphically displays the range of the
scores for the Healthy Liver Score and the corresponding liver
histology.
doi:10.1371/journal.pone.0062504.g001
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included. The Healthy Liver Score can aid in the identification of
high risk patients with obesity most likely to have normal liver
histology and exclude these patients from NAFLD screening.
There are several important limitations of our study that will
require further evaluation. First, our Healthy Liver Score was
derived from a cohort of bariatric surgery patients but before it can
be widely used it requires validation in independent surgical
cohorts. In addition, our study included only white and black
subjects, thus the Healthy Liver Score cannot be applied to other
ethnicities. This score should be evaluated more broadly,
specifically in Hispanic patients who are at highest risk of NAFLD.
In addition, the Healthy Liver Score was derived from a weight
loss surgery cohort and may be less applicable to other high risk
populations such as patients with diabetes or those referred to
specialty liver clinics. Further evaluation of the Healthy Liver
Score in broader populations is underway. Second, our study was
retrospective in nature and thus the OSA diagnosis was derived
from documentation in the medical records of OSA. We were
unable to validate whether these patients had formal sleep studies
and for those who reported CPAP use, the level of compliance
with CPAP. Prospective evaluation is needed to comprehensively
diagnosis OSA and monitor compliance. Finally, our study was
retrospective in nature and not able to quantify the amount of
weight loss patients may have experienced prior to surgery. While
varying by surgery, patients are often instructed to lose weight
immediately prior to surgery to decrease liver size (so called
‘‘shrink the liver’’ diets) and potentially decrease operative time
and complications. This pre-operative weight loss may decrease
steatosis and thus impact our findings. Future studies will need to
carefully account for any pre-operative weight loss.
In summary, our study identified factors protective against the
development of NAFLD in an otherwise high risk population. The
identification of protective factors, most importantly the absence of
OSA, offers a unique insight into the forces that ameliorate or
modulate the driving forces underlying NAFLD. Identification of
the mediators of protection, in time could lead to rational
approaches to prevention or treatment of patients at high risk of
NAFLD.
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